Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
AXON's Cash-to-Debt is ranked higher than
66% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. AXON: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AXON' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
AXON's Interest Coverage is ranked higher than
54% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AXON: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AXON' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: 33.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE % -67.58
AXON's ROE % is ranked lower than
69% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. AXON: -67.58 )
Ranked among companies with meaningful ROE % only.
AXON' s ROE % Range Over the Past 10 Years
Min: -102.82  Med: -102.82 Max: -67.58
Current: -67.58
-102.82
-67.58
ROA % -61.43
AXON's ROA % is ranked lower than
73% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. AXON: -61.43 )
Ranked among companies with meaningful ROA % only.
AXON' s ROA % Range Over the Past 10 Years
Min: -93.89  Med: -93.89 Max: -61.43
Current: -61.43
-93.89
-61.43
ROC (Joel Greenblatt) % -152500.97
AXON's ROC (Joel Greenblatt) % is ranked lower than
97% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. AXON: -152500.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AXON' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -271759.18  Med: -271759.18 Max: -152500.97
Current: -152500.97
-271759.18
-152500.97
GuruFocus has detected 2 Warning Signs with Axovant Sciences Ltd $AXON.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AXON's 30-Y Financials

Financials (Next Earnings Date: 2017-08-15 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AXON Guru Trades in Q2 2016

PRIMECAP Management 740,802 sh (-2.65%)
» More
Q3 2016

AXON Guru Trades in Q3 2016

Steven Cohen 645,300 sh (New)
Jim Simons 69,800 sh (New)
PRIMECAP Management 740,802 sh (unchged)
» More
Q4 2016

AXON Guru Trades in Q4 2016

Jim Simons Sold Out
PRIMECAP Management 719,502 sh (-2.88%)
Steven Cohen 11,500 sh (-98.22%)
» More
Q1 2017

AXON Guru Trades in Q1 2017

Steven Cohen 209,100 sh (+1718.26%)
PRIMECAP Management 2,878,930 sh (+300.13%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:AXON

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CLVS, NAS:AGIO, NAS:LGND, NAS:RARE, NAS:PTLA, NAS:SAGE, NAS:PRTA, NAS:JUNO, OTCPK:ABCZY, NAS:TBPH, OTCPK:MPSYY, NAS:SRPT, NAS:AVXS, NAS:FGEN, NAS:ICPT, NYSE:XON, NAS:DBVT, NAS:NKTR, NYSE:CBM, OTCPK:BVNRY » details
Traded in other countries:3AS.Germany,
Headquarter Location:Bermuda
Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.

Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Its drug candidate includes RVT-101. It is developing a pipeline of product candidates to comprehensively address the cognitive, behavioral and functional components of dementia. RVT-101's direct competitor is idalopirdine (Lu AE58054), a 5-HT6 receptor antagonist being developed by Lundbeck that is currently in Phase 3. In the United States, pharmaceutical products are subject to extensive regulation by the FDA.

Top Ranked Articles about Axovant Sciences Ltd

Halvorsen Funds Company Buying Neglected Drugs, Gets Stakes in 2 Biotechs Entrepreneur founds new companies focused on forgotten drugs
Andreas Halvorsen (Trades, Portfolio)’s Viking Global Investors said Wednesday it had invested in one of biotech’s hottest companies and in the process two of the companies it is involved in. Read more...

Ratios

vs
industry
vs
history
PB Ratio 13.03
AXON's PB Ratio is ranked lower than
82% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. AXON: 13.03 )
Ranked among companies with meaningful PB Ratio only.
AXON' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 14.93
Current: 13.03
0
14.93
EV-to-EBIT -13.52
AXON's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. AXON: -13.52 )
Ranked among companies with meaningful EV-to-EBIT only.
AXON' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.66  Med: 0 Max: 0
Current: -13.52
-15.66
0
EV-to-EBITDA -13.53
AXON's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. AXON: -13.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
AXON' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.66  Med: 0 Max: 0
Current: -13.53
-15.66
0
Current Ratio 5.19
AXON's Current Ratio is ranked higher than
58% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. AXON: 5.19 )
Ranked among companies with meaningful Current Ratio only.
AXON' s Current Ratio Range Over the Past 10 Years
Min: 5.19  Med: 17.9 Max: 72.47
Current: 5.19
5.19
72.47
Quick Ratio 5.19
AXON's Quick Ratio is ranked higher than
59% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AXON: 5.19 )
Ranked among companies with meaningful Quick Ratio only.
AXON' s Quick Ratio Range Over the Past 10 Years
Min: 5.19  Med: 17.9 Max: 72.47
Current: 5.19
5.19
72.47

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 13.49
AXON's Price-to-Net-Cash is ranked lower than
64% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. AXON: 13.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AXON' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.14  Med: 5.89 Max: 14.27
Current: 13.49
4.14
14.27
Price-to-Net-Current-Asset-Value 13.08
AXON's Price-to-Net-Current-Asset-Value is ranked lower than
65% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. AXON: 13.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AXON' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.1  Med: 5.89 Max: 13.84
Current: 13.08
4.1
13.84
Price-to-Tangible-Book 13.01
AXON's Price-to-Tangible-Book is ranked lower than
75% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. AXON: 13.01 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AXON' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.1  Med: 5.89 Max: 13.76
Current: 13.01
4.1
13.76
Earnings Yield (Greenblatt) % -7.42
AXON's Earnings Yield (Greenblatt) % is ranked lower than
64% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. AXON: -7.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AXON' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2519.8  Med: 0 Max: 0
Current: -7.42
-2519.8
0

More Statistics

EPS (TTM) $ -1.59
Short Percentage of Float15.44%
52-Week Range $11.01 - 25.18
Shares Outstanding (Mil)106.92

Analyst Estimate

Mar17 Mar18 Mar19 Mar20
Revenue (Mil $) 107 489
EPS ($) -1.71 -2.24 -2.46 -0.08
EPS without NRI ($) -1.71 -2.24 -2.46 -0.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NYSE:AXON

Headlines

Articles On GuruFocus.com
Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters' Apr 17 2017 
Axovant Sciences Ltd. Announces Pricing of $125M Public Offering of Common Shares Apr 11 2017 
Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares Apr 10 2017 
Axovant Sciences Announces Appointment of Dr. David Hung as Chief Executive Officer and Expansion of Apr 10 2017 
Andreas Halvorsen's Largest 2nd Quarter Buys Jul 17 2016 
Andreas Halvorsen's Viking Global Gets Control of Stakes in 2 Companies for Backing Hot Biotech Jul 14 2016 
Andreas Halvorsen Invests in Axovant Sciences Jul 14 2016 

More From Other Websites
Axovant: A New CEO Doesn't Change Anything Apr 18 2017
Axovant Sciences Ltd. Announces Closing of Public Offering and Exercise in Full of the Underwriters'... Apr 17 2017
Shark Bites: You Don't Want to Play the Gambler Today Apr 13 2017
Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Apr 12 2017
Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2% Apr 12 2017
What's Got Axovant Sciences Jumping 10% Today? Apr 11 2017
New Captain, Same Ship for Axovant Apr 11 2017
Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism Apr 11 2017
3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich Apr 11 2017
Axovant Sciences Ltd. Announces Pricing of $125M Public Offering of Common Shares Apr 11 2017
The State of Play in Axovant Sciences Apr 11 2017
[$$] The $400 Million Man Apr 10 2017
Axovant CEO David Hung Promises To Invest $10 Million As Company Moves To Raise $100 Million Apr 10 2017
Biotechs Split: Axovant Rides CEO Swap, But Celgene Partner Dives Apr 10 2017
Axovant Sciences Ltd. Announces $100 Million Public Offering of Common Shares Apr 10 2017
Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk Apr 10 2017
Why Axovant Sciences Is Soaring 25% Today Apr 10 2017
Axovant stock surges 28% on new CEO Apr 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)